Xiaohui Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Xiaohui Zhao has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Danni Wang
Department of Radiation Oncology, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China
1 shared publication- Guoying Liu
Department of Nasopharyngeal Carcinoma Sun Yat‐sen University Cancer Center the State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy Guangzhou China
1 shared publication Jie Chen
Department of Radiation Oncology, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China
1 shared publicationShuang Ma
Department of Radiation Oncology, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China
1 shared publication- Yimin Liu
Department of Radiotherapy, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
1 shared publication Yuting Qiu
Department of Radiation Oncology, Shenshan Medical Centre Memorial Hospital of Sun Yat‐sen University Shanwei China
1 shared publication
Latest Publications
- Open Access
- 14 September 2025
- Published by Wiley in Cell Proliferation
- Vol. 59 (2) , e70119
Non‐Coding RNAs in Breast Cancer Radioresistance: Mechanisms, Functional Roles and Translational Potentials
Breast cancer remains the most prevalent malignancy among women, and radiotherapy plays a pivotal role in reducing local recurrence and improving prognosis. However, the emergence of radioresistance in a subset of patients significantly compromises treatment efficacy, underscoring the need for a deeper understanding of the underlying molecular mechanisms. In recent years, non‐coding RNAs (ncRNAs) have emerged as key regulators of gene expression and have garnered increasing attention for their roles in mediating radioresistance in breast cancer. This review systematically summarises the major molecular mechanisms by which ncRNAs contribute to breast cancer radioresistance, including cell cycle regulation, DNA damage repair, programmed cell death (e.g., apoptosis, autophagy and ferroptosis), oxidative stress response, tumour microenvironment remodelling and maintenance of cancer stem cell properties. On the translational front, RNA‐based therapeutic approaches—including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), miRNA mimics and CRISPR/Cas9—offer promising avenues for radiosensitisation, yet face substantial clinical hurdles. These include immune activation, poor delivery specificity, intracellular trafficking barriers and limited stability. Advances in chemical modifications and nanoparticle‐based delivery systems—such as redox‐responsive nanocarriers—have shown potential in enhancing the efficacy and safety of ncRNA‐targeted therapies. Despite encouraging progress, clinical translation remains constrained by a lack of methodological standardisation, insufficient high‐quality clinical data, limited biomarker reliability, suboptimal target selection and unresolved safety concerns. Future efforts should prioritise optimisation of delivery platforms, validation of multi‐ncRNA biomarker panels in large, multicentre cohorts and integration of multi‐omics data to reconstruct comprehensive regulatory networks, ultimately accelerating the clinical deployment of ncRNA‐based radiosensitisation strategies.
- 14 September 2025
- Published by Wiley in Cell Proliferation
- Vol. 59 (2) , e70119
Open AccessNon‐Coding RNAs in Breast Cancer Radioresistance: Mechanisms, Functional Roles and Translational Potentials
Breast cancer remains the most prevalent malignancy among women, and radiotherapy plays a pivotal role in reducing local recurrence and improving prognosis. However, the emergence of radioresistance in a subset of patients significantly compromises treatment efficacy, underscoring the need for a deeper understanding of the underlying molecular mechanisms. In recent years, non‐coding RNAs (ncRNAs) have emerged as key regulators of gene expression and have garnered increasing attention for their roles in mediating radioresistance in breast cancer. This review systematically summarises the major molecular mechanisms by which ncRNAs contribute to breast cancer radioresistance, including cell cycle regulation, DNA damage repair, programmed cell death (e.g., apoptosis, autophagy and ferroptosis), oxidative stress response, tumour microenvironment remodelling and maintenance of cancer stem cell properties. On the translational front, RNA‐based therapeutic approaches—including antisense oligonucleotides (ASOs), small interfering RNAs (siRNAs), miRNA mimics and CRISPR/Cas9—offer promising avenues for radiosensitisation, yet face substantial clinical hurdles. These include immune activation, poor delivery specificity, intracellular trafficking barriers and limited stability. Advances in chemical modifications and nanoparticle‐based delivery systems—such as redox‐responsive nanocarriers—have shown potential in enhancing the efficacy and safety of ncRNA‐targeted therapies. Despite encouraging progress, clinical translation remains constrained by a lack of methodological standardisation, insufficient high‐quality clinical data, limited biomarker reliability, suboptimal target selection and unresolved safety concerns. Future efforts should prioritise optimisation of delivery platforms, validation of multi‐ncRNA biomarker panels in large, multicentre cohorts and integration of multi‐omics data to reconstruct comprehensive regulatory networks, ultimately accelerating the clinical deployment of ncRNA‐based radiosensitisation strategies.